Doxribtimine

Doxribtimine

SCHEMBL6518312

Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

P

The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
THRB P10828 1/20 0.62
MTOR P42345 1/20 0.62
MDM2 Q00987 1/20 0.62
NCOA1 Q15788 1/20 0.62
NCOA3 Q9Y6Q9 1/20 0.62
P2RY2 P41231 3/20 0.54
P2RY4 P51582 3/20 0.54
P2RY6 Q15077 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.50
TK1 P04183 1/20 0.50
DTYMK P23919 2/20 0.49
TK2 O00142 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxribtimine SCHEMBL787714 1.00 LMNA (0.62) LMNATHRBMTORMDM2NCOA1
Doxribtimine SCHEMBL29124320 0.96 P2RY2 (0.60) LMNATHRBMTORMDM2NCOA1
Doxribtimine SCHEMBL3951759 0.92 TK1 (0.56) LMNASMN1; SMN2TK1TK2
Cytidine SCHEMBL4468985 0.90 LMNA (0.65) LMNATHRBMTORMDM2NCOA1
Adenosine SCHEMBL23835231 0.89 DTYMK (0.66) SMN1; SMN2DTYMK
Cytidine SCHEMBL574775 0.88 LMNA (0.62) LMNATHRBMTORMDM2NCOA1
Guanosine SCHEMBL10528215 0.87 F2 (0.64) LMNATHRBMTORMDM2NCOA1
Cytidine SCHEMBL574822 0.87 LMNA (0.67) LMNATHRBMTORMDM2NCOA1
Doxecitine SCHEMBL9803658 0.87 LMNA (0.50) LMNASMN1; SMN2TK1TK2
Doxribtimine SCHEMBL325199 0.87 TK1 (0.62) LMNASMN1; SMN2TK1TK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6955915-B2 Apparatus comprising polymers AFFYMETRIX, INC. (US) 2005-10-18 US disclosed
US-20050208537-A1 Very large scale immobilized polymer synthesis AFFYMETRIX, INC. (US) 2005-09-22 US disclosed
US-20050095652-A1 Apparatus comprising polymers AFFYMETRIX, INC. (US) 2005-05-05 US disclosed
US-20050079529-A1 Very large scale immobilized polymer synthesis AFFYMETRIX, INC. (US) 2005-04-14 US disclosed
EP-1046421-B1 Methods and reagents for very large scale immobilized polymer synthesis AFFYMETRIX INC (US) 2003-07-02 EP disclosed
US-20030108899-A1 Very large scale immobilized polymer synthesis AFFYMETRIX, INC. (US) 2003-06-12 US disclosed
US-6506558-B1 Deprotecting nucleoside, nucleotide or amino acid to form polypeptide or polynucleotide AFFYMETRIX INC. 2003-01-14 US disclosed
US-20020137096-A1 Apparatus comprising polymers AFFYMETRIX, INC. (US) 2002-09-26 US disclosed
US-6420169-B1 Apparatus for forming polynucleotides or polypeptides AFFYMETRIX, INC. 2002-07-16 US disclosed
EP-0562025-B1 Compounds and their use in a binary synthesis strategy AFFYMETRIX INC (US) 2001-02-07 EP disclosed
EP-1046421-A2 Methods and reagents for very large scale immobilized polymer synthesis Affymetrix, Inc. (US) 2000-10-25 EP disclosed
US-5424186-A Biosynthesis of oligonucleotides on solid substrate by irradiation of predefined segments to remove blocking agents; then coupling with nucleotide AFFYMAX TECHNOLOGIES N.V. (AN) 1995-06-13 US disclosed
EP-0562025-A4 1994-03-30 EP disclosed
EP-0562025-A1 VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS AFFYMAX TECHNOLOGIES N.V. (AN) 1993-09-29 EP disclosed
WO-1992010092-A1 VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS AFFYMAX TECHNOLOGIES N.V. (AN) 1992-06-25 WO disclosed